SNG: Jamjoom Pharma partners with Bio-Thera to secure Cosentyx biosimilar in MENA

About this update from Jamjoom Pharmaceuticals Factory Co.

First published: 16-Sep-2025 11:31:28Staff WriterRiyadh – Jamjoom Pharmaceuticals Factory Company (Jamjoom Pharma) has signed a strategic commercialization agreement with Bio-Thera Solutions Limited, a global biopharmaceutical firm specializing in innovative therapies and biosimilars.Under the partnership, the Saudi-listed group will have the exclusive rights to commercialize BAT2306 - a proposed biosimilar to Novartis’ Cosentyx (secukinumab), across the MENA region, according to a press release.Jamjoom Pharma will handle regulatory submissions, market access, and commercialization in MENA.Meanwhile, Bio-Thera will oversee product development and global manufacturing from its facilities in Guangzhou, China.Tarek Hosni, CEO of Jamjoom Pharma, said: “By joining forces with Bio-Thera, we are combining world-class biosimilar development with Jamjoom’s deep regional expertise, strong commercial capabilities, and commitment to delivering high-quality, affordable therapies.”“This agreement strengthens our leadership in the biopharmaceutical sector and reinforces our role as a trusted partner in improving patient outcomes,” Hosni added.Bert Thomas, Senior Vice President of Business Development, noted: “Partnering with JamJoom Pharma to bring BAT2306 to patients in the MENA region is a demonstration of that commitment. We are proud to partner with Jamjoom Pharma and look forward to a successful collaboration.”All Rights Reserved - Mubasher Info © 2005 - 2025 Provided by SyndiGate Media Inc. (Syndigate.info).Disclaimer: The content of this article is syndicated or provided to this website from an external third party provider. We are not responsible for, and do not control, such external websites, entities, applications or media publishers. The body of the text is provided on an “as is” and “as available” basis and has not been edited in any way. Neither we nor our affiliates guarantee the accuracy of or endorse the views or opinions expressed in this article. Read our full disclaimer policy here.

View stock analysis, news, and events for Jamjoom Pharmaceuticals Factory Co.